Increasingly, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are assuming a pivotal role in diabetes care. Current treatment algorithms recommend GLP-1 RAs as second-tier agents and for avoidance of weight gain and hypoglycemia in patient-centered treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). However, treatment algorithms may not always keep pace with recent developments. The amount of information relevant to the clinical use of GLP-1 RAs continues to increase as trial reports are presented and clinical experience grows. In the past 12 years, over 200 clinical trials for GLP-1 RAs have been published — more than 100 of them in the past 3 years. In the interest of promoting evidence-based, patient-centered care for people with T2DM, practicing endocrinologists should leverage resources to increase their awareness of recent information regarding the efficacy, safety, and nonglycemic effects of GLP-1 RAs.
In this activity, participants will be given the opportunity to analyze up to 3 case studies, focusing on the role of GLP-1 RAs in T2DM. Each case study exercise will contain clinical information about GLP-1 RA therapy that can be accessed by the user at their direction. Throughout the activity, participants will collect key information consistent with each patient’s preferences and goals, assess their current treatment T2DM regimen, and evaluate the clinical evidence for GLP-1 RA therapy in the context of the patient case.